AI Article Synopsis
- A novel case study highlights the use of camrelizumab, an immune checkpoint inhibitor, combined with chemotherapy for a 74-year-old man with advanced bladder cancer who has positive PD-L1 expression and high tumor mutational burden (TMB).
- The patient experienced a partial response to the treatment, achieving an impressive progression-free survival of 11 months.
- This is the first documented instance of this treatment combination for advanced bladder cancer, indicating potential new pathways for immunotherapy research in similar cases.
Article Abstract
Background: There has been no report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive programmed death-ligand 1 (PD-L1) expression and high tumor mutational burden (TMB). More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor.
Case Summary: We report the case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high TMB. The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with a progression-free survival of 11 mo.
Conclusion: This is the first report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive PD-L1 expression and high TMB.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727277 | PMC |
| http://dx.doi.org/10.12998/wjcc.v10.i1.254 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!